Our Insights
The thought leaders at Herspiegel Consulting help you keep your finger on the pulse of what’s happening in the pharmaceutical and biotech industry by sharing our insights with our blog and white papers. From deciphering new healthcare reform policies to assessing market access challenges to evaluating novel marketing trends, we are constantly looking to find new healthcare trends that we believe will reshape the industry.
Make sure you check out our blog and white papers on a regular basis. They’re guaranteed to stimulate and challenge you!
Our White Papers
This whitepaper outlines how copay cards were intended to address patient affordability concerns and how copay accumulators and maximizers impact that process. However, there are steps brand leaders can take to reduce exposure to these programs.
This presentation focuses on recent innovations in Oncology Clinical Trials design and the Oncology NDA approval process. In October 2018, the FDA released several new Guidances, including one which covers the use of Minimal Residual Disease (MRD) in clinical trials for hematological malignancies, and another regarding clinical trials for rare genetic variants of a disease. The FDA also began two new pilot programs to increase the efficiency of the NDA process, the Real Time Oncology Review (RTOR) Pilot Program which allows for submission of data prior to submission of a complete NDA, and the Assessment Aid Pilot Program which provides a template for NDA submissions.
This whitepaper outlines how copay cards were intended to address patient affordability concerns and how copay accumulators and maximizers impact that process. However, there are steps brand leaders can take to reduce exposure to these programs.
IO Landscape Over 50,000 cancer patients needed for IO trials, but will it make a dent?We are in the midst of an explosion of clinical targets within the immuno-oncology field which has resulted in impactful advancements in cancer care.
All medicines in this list have the potential to be gamechangers.
A consultant should be someone who provides expert advice professionally. Engaging a consultant provides access to deeper levels of expertise than would be financially feasible to retain in‐house on a long‐term basis. Organizations can control expenses and risk by purchasing as much service as desired at a given time, sometimes flexing up and down as need or budget dictates.